Key Highlights
- PepGen (NASDAQ:PEPG) was trading up 8.82% at USD 4.16 in intraday market data on Thursday, November 19, 2026, and no company announcement dated that day was found in searches.
- The company priced a public offering of 25 million shares at USD 5.00 on November 11, 2026, for expected gross proceeds of USD 125 million before fees.
- Phase 2 data for PGN-EDODM1 showed mean splicing correction of 46.5% at the 10 mg/kg dose, with five of six participants above 20% and four above 50%.
- Cash, equivalents and marketable securities were USD 104.8 million at September 30, 2026, and the net loss for the third quarter was USD 19.4 million.
Shares Trade Below the USD 5 Offering Price
PepGen (NASDAQ:PEPG) was trading up 8.82% at USD 4.16 on Thursday, November 19, 2026, in intraday market data. That is about 16.8% below the USD 5.00 offering price, simple arithmetic on two published numbers. The company announced on November 11 an underwritten offering of 25 million common shares, with a 30-day option for underwriters to buy up to 3.75 million more shares, and closing expected on or about November 13. Proceeds are for clinical development, Working Capital and general corporate purposes. No announcement dated November 17 to November 19 was found, so today's gain is not tied to a new company event, and a sub-USD 5 stock can move sharply on thin trading.
Phase 2 Data Behind the Financing
PepGen is a clinical-stage biotechnology company whose lead candidate PGN-EDODM1 targets myotonic dystrophy type 1. On November 10 it reported data from the 10 mg/kg cohort of the FREEDOM2-DM1 study, with mean splicing correction of 46.5%. Participants also improved on hand opening time, grip strength and walking speed, with no serious adverse events or dose-limiting toxicities. A monitoring board recommended moving to the 12.5 mg/kg cohort, which is fully enrolled, with results expected in the first half of 2027. Additional open-label extension data are planned for January 2027. The offering was announced the next day, a common pattern when a small biotech raises capital after positive data.
Cash Runway, Clinical Hold and Dilution Math
Before the raise, cash was USD 104.8 million at September 30, which management said funds operations into 2028. Adding the USD 125 million gross proceeds gives roughly USD 229.8 million before fees and expenses, a calculated figure that excludes later spending. The third-quarter net loss was USD 19.4 million, or USD 0.28 a share, with Research and Development expenses of USD 14.5 million. The main risk is an FDA partial clinical hold imposed in March 2026 after nonclinical findings in mice. A potential end-of-Phase 2 regulatory meeting is targeted for the second half of 2027 and depends on the hold being lifted. The new shares also add to the share count, which dilutes existing holders, and quoted moves in low-priced stocks can reverse.
Where Things Stand
The gain looks like a bounce within a larger financing story, because no company announcement dated today was found. PepGen (NASDAQ:PEPG) is trading up 8.82% at USD 4.16, still below the USD 5.00 price paid by new investors in the offering. The supports are encouraging splicing data, a USD 125 million raise and a runway that was already guided into 2028. The offsets are an unresolved FDA partial hold, dilution and early-stage trial risk. Watch for the closing of the offering, any change in the hold and the January 2027 extension data.


_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)

Please wait processing your request...